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Abstract
Background: Immunotherapeutic strategies to stimulate anti-tumor immunity are promising approaches for cancer
treatment. A major barrier to their success is the immunosuppressive microenvironment of tumors, which inhibits the
functions of endogenous dendritic cells (DCs) that are necessary for the generation of anti-tumor CD8+ T cells. To overcome
this problem, autologous DCs are generated ex vivo, loaded with tumor antigens, and activated in this non-suppressive
environment before administration to patients. However, DC-based vaccines rarely induce tumor regression.
Methodology/Principal Findings: We examined the fate and function of these DCs following their injection using murine
models, in order to better understand their interaction with the host immune system. Contrary to previous assumptions, we
show that DC vaccines have an insignificant role in directly priming CD8+ T cells, but instead function primarily as vehicles
for transferring antigens to endogenous antigen presenting cells, which are responsible for the subsequent activation of T
cells.
Conclusions/Significance: This reliance on endogenous immune cells may explain the limited success of current DC
vaccines to treat cancer and offers new insight into how these therapies can be improved. Future approaches should focus
on creating DC vaccines that are more effective at directly priming T cells, or abrogating the tumor induced suppression of
endogenous DCs.
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Introduction
Therapeutic vaccines are a considered a realistic approach for
cancer immunotherapy, because animal studies have shown that
recognition of tumor associated antigens (TAAs) by cytotoxic T
lymphocytes can lead to the destruction of tumor cells [1,2,3]. In
order to generate tumor-specific T cells with full effector function
they first must undergo priming by dendritic cells (DCs), the
antigen presenting cell (APC) most efficient at initiating potent
CD8+ T-cell responses [4,5]. Therefore, understanding how to
modulate DC functions may be essential to therapeutically
inducing anti-tumor immune responses [6,7]. The immunomod-
ulatory activity of DCs is regulated by the process of maturation.
In response to environmental signals such as pathogens or
inflammatory cytokines, immature DCs undergo phenotypic and
qualitative changes to become mature DCs, characterized by
presentation of peptides bound to major histocompatibility
complexes (MHC), high surface expression of co-stimulatory
molecules, secretion of cytokines, and potent T cell stimulatory
abilities. Depending upon the maturation stimuli, DCs instruct T
cells towards different types of immune responses [8,9]. Thus, the
development of mature DCs with the essential properties for
induction of effective anti-tumor immunity is critical.
One significant barrier to therapeutic stimulation of anti-tumor
immunity is constituents of the tumor microenvironment [10] such
as secreted immunosuppressive factors [11], myeloid-derived
suppressor cells [12], and regulatory T cells [13], that adversely
affect DC activation and consequently blunt the generation of
anti-tumor immunity. Furthermore, antigen presented to naı ¨ve T
cells by DCs that were not properly activated can lead to T cell
tolerance [14,15,16]. To circumvent this problem, many studies
have focused on optimizing the antigen presentation function of
DCs ex vivo such that these DCs can be adoptively transferred back
into the in vivo environment. Ideally, this should yield DCs that,
following injection, traffic to the draining lymph node and
efficiently activate T cells, leading to the generation of an effective
immune response [17,18].
The optimization of ex vivo DC manipulation has focused
primarily on maturation stimuli to enhance the expression of co-
stimulatory molecules, secretion of pro-inflammatory cytokines,
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lymphoid organs. Additionally, the form of antigen used for
loading DCs is a major consideration. The most commonly used
form of antigens, are pre-determined immunogenic peptide
epitopes derived from TAA, which are restricted to specific
MHC haplotypes; or whole tumor antigens, which are theoreti-
cally more advantageous than peptide antigens because they can
be processed into epitopes that can be presented regardless of
patients’ MHC haplotypes.
Several clinical trials conducted over the past decade have
demonstrated that DC vaccines can prime and boost antigen-specific
CD8+ T cells in humans. However, their clinical efficacy remains to
be definitively demonstrated [6,19,20,21]. The lack of success has
been variously attributed to several factors: administration of
relatively low cell numbers of DCs, suboptimal route of administra-
tion, improper antigen dose, poor choice of antigenic targets,
unsuitable maturation state of DCs, and inappropriate frequency of
injections. However, understanding exactly which of these concerns
represent true problems may be difficult because little is known
regarding the fate and function of ex vivo generated DCs after they
have been injected. Because tracking these events in patients in a
controlled manner is not feasible, we utilized a murine model of DC
vaccination to better understand the events following DC injection.
We show here that ex vivo derived DC vaccines have an insignificant
role in the direct priming of T cells in vivo. Instead, evidence is
provided that DC vaccines indirectly prime naı ¨veCD8+ Tc e l l sin vivo
by transferring antigens to endogenous cells, which subsequently
present them to CD8+ T cells.
Results
CD8+ T cell priming by peptide loaded DC vaccine
requires endogenous antigen presenting cells
To investigate the immunogenicity of DC vaccines, we first
established a murine model to monitor the in vivo activation of
antigen-specific CD8+ T cells following vaccination. Mice were
intravenously injected with ex vivo derived DCs pulsed with the
MHC class I-restricted epitope of the ovalbumin (OVA) protein,
OVA257–264 (peptide-DCs). As a control, mice were immunized
with attenuated Listeria monocytogenes (Lm) expressing OVA
(LmOVA). Immunization of wild type C57BL/6 (B6) mice with
either LmOVA or peptide-DCs elicited an OVA257–264-specific
immune response as demonstrated by antigen-specific IFN-c
production by CD8+ T cells (Fig. 1A). While the T cell response
to LmOVA should depend on antigen presentation by the
endogenous bone-marrow-derived hematopoietic cells [22], the
priming by peptide-DCs in these mice could be a result of either
direct interaction of the injected DCs with endogenous T cells, or
antigens from the injected DCs captured by host cells and
subsequently presented to T cells.
Figure 1. Peptide-pulsed DC vaccines require help from host immune cells to induce a maximal CD8+ T cell response. (A) Wild type
C57BL/6 (B6) mice were vaccinated with either attenuated LmOVA (1610
6 CFU/mouse), OVA257–264 (100 ng/ml)–pulsed LPS-matured B6 DCs
(peptide-DCs, 1610
6 cells/mouse), or unpulsed LPS-matured B6 DCs (DC alone, 1610
6 cells/mouse). On day 7, the percentage of IFN-c producing
CD8+ T cells was determined (horizontal bar = mean). (B)B 6 RB6 (B6) and Bm1RB6 (Bm1) marrow chimeras (BMCs) were adoptively transferred with
5,000 naı ¨ve OT-1 T cells and vaccinated the following day with LmOVA (1610
6 CFU/mouse), peptide-DCs (1610
6 cells/mouse), or DCs alone
(1610
6 cells/mouse). The immune response was assessed on days 7 and 18 post-vaccination. (C) Antigen-specific IFN-c production by splenic CD8+ T
cells was measured on day 7. Data are mean + s.d. for 3 mice per group and are representative of 3 experiments. (D) In vivo killing of OVA257–264
peptide coated target cells in the spleen between days 18 and 20 was assessed. Specific killing was normalized to the internal control of target cells
coated with an irrelevant peptide from the Sendai virus nucleoprotein, NP324–332. Data are mean 6 s.d. for 3 mice per group and are representative of
2 experiments.
doi:10.1371/journal.pone.0011144.g001
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effect of the injected DCs, we repeated these vaccinations in bone
marrow chimeric mice (BMCs) that lack a hematopoietic
compartment able to present the OVA257–264 peptide. This was
accomplished by reconstituting lethally irradiated wild type mice
with bone marrow from Bm1 mice, which express a mutant H-
2K
b allele (H-2K
bm1) that prevent proper interaction of the
OVA257–264-MHC complex with its cognate CD8+ T cell [23].
We confirmed donor-specific tolerance after allogeneic bone
marrow transplantation (Fig. S1). Wild type and Bm1-derived
bone marrow cells will reconstitute a T cell compartment with
differing repertoires of naive antigen-specific T cells therefore, we
normalized the number of OVA257-264-specific T cells by
adoptively transferring 5,000 naive OT-I CD8+ T cells, into each
mouse one day prior to vaccination (Fig. 1B).
As expected, mice reconstituted with Bm1 bone marrow (Bm1
BMCs) did not elicit an OVA257–264-specific CD8+ Tc e l l
response after vaccination with LmOVA, in contrast to mice
reconstituted with wild ty p eb o n em a r r o w( B 6B M C s )( Fig. 1C).
However, following intravenous vaccination with peptide-DCs,
the number of IFN-c producing CD8+ Tc e l l sg e n e r a t e dw a s
significantly reduced in Bm1 BMCs (Fig. 1C), and this small
number of T cells primed in the Bm1 BMCs also exhibited a
reduced effector cell function (Fig. 1D). These results suggest
that the T cell priming observed after vaccination with peptide
DCs in Fig. 1A requires a host with a hematopoietic
compartment capable of capturing and re-presenting the
vaccine derived antigen.
Antigen transfer from the injected DCs to endogenous APCs
may occur either by shedding of peptides or transfer of intact
peptide-MHC complexes [24,25], possibly via exchange of plasma
membranes and associated proteins between cells [26]. Contact-
dependent transfer of peptide-MHC complexes from ex vivo
derived DCs to splenic cell populations can occur with great
efficiency in vitro (Fig. S2). However, the inefficient T cell
activation in Bm1 BMCs suggests that translocation of peptide-
MHC complexes to host APCs is unlikely the source responsible
for T cell priming in B6 BMCs.
Priming of CD8+ T cells by DCs loaded with protein
antigen also requires endogenous antigen presenting
cells
The heterogeneous nature of most tumor antigens and patient
MHC haplotypes limits the practicality of externally-loaded pre-
determined peptides as an antigen source for vaccines. Conse-
quently, DCs are often loaded with antigens that require
processing. To mimic this vaccine approach, we used DCs
generated ex vivo from mice (Act-mOVA mice) [27] that
constitutively express OVA protein under the actin promoter.
DCs from Act-mOVA mice (ActOVA DCs) process the
endogenous antigen in the MHC class I pathway and express
OVA257–264-MHC class I complexes on their cell surface at a level
comparable to the peptide-DCs used for vaccination (Fig. 2A),
and both types of DCs stimulate T cells in vitro with comparable
potency (Fig. 2B). When mice were intravenously immunized
with ActOVA DCs using the same strategy described in Fig. 1B,
we again observed the same requirement for host APCs in
generating a maximal CD8+ T cell response as we had with
peptide-DCs (Fig. 2C). Thus, regardless of whether the OVA
antigen was originally expressed in DCs (ActOVA DCs) or
externally loaded on the surface as a pre-determined epitope
(peptide-DCs), maximal priming of OVA-specific T cells requires
host APCs.
The requirement for host antigen presenting cells does
not depend on the route of DC vaccine delivery
Since the route of injection influences the sites DCs reach and thus
may affect their function, we repeated our vaccination using
subcutaneous injections. We also took this opportunity to extend
our findings in an additional BMC system, in which irradiated wild
type B6 mice were reconstituted with bone marrow from the MHC
class I-deficient K
bD
b KO mice (K
bD
b KO BMCs) [28,29]. Similar
to our results with intravenously delivered DCs, transfer of antigens to
host APCs was required for efficient CD8+ T cell priming (Fig. 3A).
The indirect roleof the injected DCs in T cellpriming was not due to
a lack of exit from the injection site, because the DCs migrated to the
draining lymphnode(LN),albeit with a very low frequency of#0.5%
of total injected cells (Fig. 3B). This percentage of DCs to migrate is
consistent with findings from other groups [30,31,32,33]. Addition-
ally, the DCs were viable and had not been internalized by host cells
when detected in the draining LN two days after injection (Fig. 3C).
Our data demonstrate that, irrespective of the route of their delivery,
optimal generation of systemic immune responses by DC vaccines
requires host APCs.
Differential requirements for endogenous DCs by
peptide-loaded DCs versus protein expressing DCs
Because DCs are the APC most efficient at priming CD8+ T-
cells [6] it seemed likely that they might be the cell type responsible
for the presentation of the DC vaccine-derived antigens we
observed. To investigate this possibility, we repeated our
vaccinations in irradiated wild type mice reconstituted with bone
marrow from mice that express the primate diptheria toxin
receptor (DTR) under control of the CD11c promoter (CD11c-
DTR BMCs) [22] (Fig. 4A). Treatment of these mice with
diptheria toxin (DT) throughout the duration of the experiment
selectively eliminated the CD11c
high expressing DCs as confirmed
by flow cytometry (Fig. S3), and the lack of a T cell response in
DT treated mice after infection with LmOVA (Fig. 4B).
Both peptide-DC and ActOVA DC vaccines primed a CD8+ T
cell response efficiently in non-DT treated CD11c-DTR BMCs, as
evidenced by the percentage of cellspositive for OVA257–264-tetramer
staining and antigen-specific IFNc and TNF production by CD8+ T
cells 7 days post-vaccination (Fig. 4B). In DT-treated mice,
vaccination with ActOVA DCs induced a poor T cell response,
demonstrating that they rely substantially on host DCs to cross-prime
antigens. However, the frequency of CD8+ T cells primed after
delivery of peptide-DCs was not affected by the DT treatment.
In this model, T cell activation may reflect direct interaction of
peptide-DCs with naive CD8+ T cells. However, in conjunction
with previous results in Bm1 BMCs (Fig. 1C), it is possible that
peptide antigens from the injected peptide-DCs were transferred
to cell types other than CD11c+ DCs, which subsequently
activated naı ¨ve CD8+ T cells.
To determine how ActOVA DCs were unable to take
advantage of peptide transfer to endogenous cells for T cell
activation, we compared the stability of surface MHC-bound
peptides on ActOVA DCs to their stability on peptide-DCs. We
found that there is a greater dissociation rate of peptides that are
externally loaded onto surface MHC class I molecules, than of
peptides presented by ActOVA DCs, which are intracellularly
processed and loaded (Fig. 4C). Compared to ActOVA DCs,
peptide-DCs seem to transfer their surface MHC-bound peptides
more readily to host cells. We also confirmed that non-specific
binding of peptides to non-MHC molecules on the peptide-DCs
does not contribute to transfer of antigens to host cells resulting in
T cell activation (Fig. S4).
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the quality of CD8+ T cellsprimed during an immune response [34].
The phenotypes of the OVA257–264-tetramer positive T cells primed
by either type of DC vaccine, in the presence or absence of
endogenous DCs were indistinguishable (Fig. S5). Because it seemed
unlikely that non-CD11c+ DC populations would be able to
efficiently prime a robust T cell response, we considered the
possibility that the priming, which relied on endogenous hemato-
poetic cells, but was independent of endogenous DCs might be
limited to very immunogenic peptides such as OVA257–264.W h e nw e
used a peptide-pulsed DC vaccine loaded with a less immunogenic
peptide, gp33–41 from the lymphocytic choriomeningitis virus
(LCMV) glycoprotein, non-DC host cells in DT-treated mice were
unable to generate the maximal CD8+ T cell response to this epitope
(Fig. 4D).T cellresponses to tumor antigensare better represented in
this scenario, and therefore our results indicate that endogenous DCs
are important for the effectiveness of both peptide-pulsed and whole
protein loaded DC vaccines.
Discussion
Our finding that the effectiveness of murine DC vaccines relies
considerably on endogenous APCs, has important implications for
the use of DC vaccines in cancer immunotherapy. Currently, the
efficacy of ex vivo-derived DC-based immunotherapy has still to be
proven for human cancers [35,36,37], and the limited success has
been attributed to a variety of factors regarding the preparation
and administration of the vaccine, the disease stage of participants
in experimental trials, or the heterogeneous nature of most tumors.
The dependence on endogenous cells by antigen-loaded DCs
could be a key underlying explanation for poor vaccine efficacy,
especially considering that the clinical trial participants with late
disease stage are likely to have an immunosuppressive tumor
environment, rendering the endogenous cells ineffective.
We show that peptide-DCs and whole antigen-loaded DCs may
have less substantial roles in directly activating naı ¨ve CD8+ T cells
in vivo. Although OVA257–264-pulsed DCs were able to induce an
Figure 2. DC vaccines expressing protein antigens delivered intravenously require help from host cells for maximal activation of
naı ¨ve CD8+ T cells. (A) By measuring the relative activation of B3Z T cell hybridomas, the cell surface OVA257–264-MHC complex levels on different
LPS-matured bone marrow derived DC conditions were assessed. The DC conditions included LPS-matured B6 DCs, OVA257–264 (10 ng/ml)–pulsed
LPS-matured B6 DCs, and ActOVA DCs. (B) To determine the ability of these DCs to activate naı ¨ve CD8+ T cells in vitro, they were cultured with CFSE-
labeled naı ¨ve OT-1 T cells at various ratios. On day 3, the percentage of proliferating cells was analyzed by flow cytometry. (C)B 6 RB6 (B6) and
Bm1RB6 (Bm1) bone marrow chimeras (BMCs) were adoptively transferred with 5,000 naı ¨ve OT-1 CD8+ T cells. The next day, these mice were
vaccinated intravenously with one of the following: B6 DCs (0.5610
6 cells/mouse), attenuated LmOVA (1610
6 CFU/mouse), or ActOVA DCs
(0.5610
6 cells/mouse). The frequency of OVA257–264-tetramer positive and IFN-c producing CD8+ T cells was determined 7 days post-vaccination
(mean 6 s.d. for 4 mice per group).
doi:10.1371/journal.pone.0011144.g002
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DT-treated CD11c-DTR BMCs (Fig. 4B), we hesitate to
conclude that they were directly interacting with T cells in vivo
for two reasons. First, DCs loaded with a less immunogenic
peptide, gp33–41 were unable to induce an optimal antigen-specific
CD8+ T cell response in mice lacking endogenous CD11c+ DCs
(Fig. 4D). Secondly, injection of OVA257–264-pulsed B6 DCs
intravenously or subcutaneously into hosts that lack hematopoietic
cells capable of presenting antigens resulted in a significant
reduction of antigen-specific CD8+ T cells (Fig. 1C and Fig. 3A).
Figure 3. DCs vaccinated subcutaneously require MHC class I expression on the host immune cells to fully activate naı ¨ve CD8+ T




b KO) bone marrow chimeras (BMCs) were adoptively transferred with 5,000 naı ¨ve OT-1 CD8+ T cells. The
next day, they were vaccinated subcutaneously in the footpad with one of the following: LPS-matured B6 DCs (0.5610
6 cells/mouse), attenuated Lm-
OVA (1610
6 CFU/mouse), or LPS-matured ActOVA DCs (0.5610
6 cells/mouse). The frequencies of OVA257–264-tetramer positive CD8+ T cells in the
spleen (individual mice) and draining lymph node (LN, combined value of from mice of each condition) and IFN-c producing CD8+ T cells in the
spleen of each mouse were determined 7 days post-vaccination (data are mean 6 s.d. for 4 mice per group). (B) To track migration of DCs to the
draining LN, CFSE-labeled or –unlabeled LPS-matured DCs (1610
6 cells/mouse) were injected subcutaneously in the foot pad of naı ¨ve mice. The
popliteal LNs were removed 2 and 3 days post-injection. Cells were gated on the live (7-AAD negative) and CD11b+ population using flow cytometry
to analyze the percentage (0.1–0.3%) of DCs that migrated. (C) CFSE-labeled CD45.1 donor DCs were injected subcutaneously in the footpad of
CD45.1-CD45.2+ wild type mice. Two days later the popliteal LNs were removed and cells were stained with anti-CD45.1 and anti-CD45.2 antibodies.
doi:10.1371/journal.pone.0011144.g003
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PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11144Figure 4. Endogenous CD11c
high DCs are recipients of antigens derived from DC vaccines, that are essential for activating naı ¨ve
CD8+ T cells in vivo. (A-B, D) CD11c-DTR BMCs were treated with diptheria toxin (DT) on days 24, 21, and 2 relative to the day of vaccination.
Naı ¨ve transgenic CD8+ T cells were adoptively transferred intravenously on day 21. Antigen-specific T cell responses were analyzed on day 7 post-
Indirect Priming by DC Vaccine
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bound to their surface MHC molecules, therefore are unlikely to
be used as an antigen source for cross presentation into the MHC
class I antigen presentation pathway, if internalized by a recipient
cell. It is most likely that peptides are being transferred directly
onto the surface MHC class I molecules of host APCs for their
subsequent presentation. In theory, any cell type expressing MHC
class I molecules and co-stimulatory molecules could present the
antigenic peptide donated from peptide-DCs to activate naı ¨ve T
cells. Possibly, APCs not eliminated by DT treatment, such as
plasmacytoid DCs [38,39,40] participated in the priming of T
cells. However, we demonstrated with gp33–41 peptides that the
dependence of peptide transfer from injected DCs to non-CD11c+
DC endogenous cell populations does not apply for all antigens.
Similar to peptide-DCs, priming of CD8+ T cells by ActOVA
DCs was inefficient in mice with endogenous cells lacking the
appropriate MHC molecules to present the OVA257–264 peptide
(Fig. 2C and Fig. 3A). In the CD11c-DTR model, the OVA
antigen expressed by ActOVA DCs is cross-presented specifically
by endogenous DCs. This data is consistent with previous reports
that DCs are required for the cross-priming of cell-associated
antigens [22]. Protein antigens can be transferred and processed
for MHC class I presentation by host DCs following phagocytosis
of apoptotic [41] or necrotic [42,43] ActOVA DCs. Although
these results are expected, we were surprised that there was a
difference in the requirement of endogenous CD11c+ DCs for T
cell activation by ActOVA DCs versus OVA257–264-pulsed DCs.
An in vitro assay confirmed that peptides loaded externally onto cell
surface bound MHC I molecules (peptide-DCs) are less stable than
those internally processed on loaded onto MHC I molecules, as in
ActOVA DCs (Fig. 4C). We conclude that because ActOVA DCs
may not shed peptides as readily as OVA257–264-pulsed DCs in vivo,
they are dependent on cross-presentation by host DCs.
Under priming conditions where antigen transfer by cross-
presentation or by peptide transfer to MHC class I molecules was
not permitted, there was some residual T cell expansion. The
specific interaction of injected ex vivo derived DCs and antigen-
specific T cells has been visualized in the draining LN of mice [17],
therefore it is possible that the small amount of T-cell activation
may have resulted from direct priming by injected DCs.
Alternatively, several groups have described the transfer of
peptide-MHC complexes to recipient cells from either secreted
exosomes [44,45,46], live cells via the acquisition of plasma
membranes [26], or dead cells in a process called ‘‘cross-dressing’’
[24,25]. In vitro, the transfer of peptide-MHC complexes from ex
vivo derived DCs to splenic cell populations takes place efficiently
(Fig. S2). However, we conclude that this mechanism is not as
effective in vivo, because the expression of an appropriate MHC
haplotype on host cells is essential for a proper T cell response.
More importantly, we showed that the residual T cells primed in
Bm1 BMCs after administering peptide-DCs were not able to
effectively kill target cells (Fig. 1D). In this setting, the initial
number of antigen-specific CD8+ T cells produced early during
immune activation seems to be important for the generation of a
memory response. Altogether our data show that DC vaccines
overcome their inability to directly prime T cells in vivo by
transferring antigens to hematopoietic cells for subsequent antigen
presentation.
In order for endogenous DCs to properly prime naı ¨ve CD8+ T
cells, they must undergo maturation. Therefore, in addition to
acting as an antigen source, the injected DCs may also cause
activation of endogenous recipient DCs without further stimula-
tion. It has been shown that cross-presentation of OVA-loaded
irradiated Bm1 or B6 splenocytes by host APCs results in
proliferation of antigen-specific T cells, even in the absence of
additional adjuvants [47,48]. In these circumstances, the activa-
tion of host DCs required for efficient cross-presentation may be
explained by the potential release of TLR ligands during donor
cell death [49]. In our studies, it is possible that the eventual death
of the injected LPS-treated DC vaccines in this study may have
contributed to the successful T cell activation in mice with a wild
type hematopoietic compartment. Phagocytosis of LPS-treated
apoptotic cells has recently been shown to mature DCs in a TLR-4
dependent manner [50]. Indeed, we showed that injection of mice
with DCs coated with LPS caused an upregulation of maturation
markers on a small number of endogenous splenic DCs (Fig. S6),
pointing to a mechanism by which host APCs can undergo
activation following exposure to adoptively administered DCs.
However, the immunosuppressive nature of most cancers is
unfavorable to the proper activation of host DCs [10] and is
therefore an obstacle for any vaccine that relies on these cells to
initiate a T cell response. We speculate that this is one explanation
for the poor efficacy of DC vaccines to eliminate tumors in clinical
trials [20]. In this context, the adjuvant activity of the administered
ex vivo-derived DCs may be inadequate for proper naı ¨ve T cell
stimulation, and the benefits of antigen transfer could go
undetected, unless combined with other immunotherapeutic
strategies that focus on inhibiting the factors that contribute to
the immunosuppressive tumor environment [20]. Future anti-
cancer immunotherapeutics might also benefit from activating and
targeting antigens to endogenous DCs directly [51].
Materials and Methods
Mice, bacteria strains, and cells
C57BL/6, Balb/c, and OT-1 Rag KO mice were purchased
from Taconic. CD11c-DTR, Act-mOVA, K
bD
b KO, and Bm1
mice were purchased from Jackson Laboratory. Mice were 5 weeks
of age at the start of each experiment. All experimental procedures
involving mice were performed with the approval of the New York
University School of Medicine Committee on Animal Research
under the protocol number 070407-02. Attenuated Listeria
monocytogenes (Lm) expressing OVA (LmOVA) and the B3Z T cell
hybridomas were provided by Anza Therapeutics. B3Z assays
were performed as previously described [52]. Mouse bone
marrow-derived DCs were generated as described previously
[53]. Briefly, 2610
6 bone marrow cells were cultured in media
supplemented with 20ng/ml recombinant murine GM-CSF
vaccination. (B) Mice previously injected with naı ¨ve OT-1 CD8+ T cells (5,000 cells/mouse) were left untreated or vaccinated with one of the following:
attenuated LmOVA (1610
6 CFU/mouse), LPS-matured B6 DCs pulsed with 10 ng/ml of OVA257–264 peptide (OVA257+DCs, 0.5610
6 cells/mouse), or
LPS-matured ActOVA DCs (0.5610
6 cells/mouse). The percentages of OVA256–264-tetramer positive and of IFN-c- and TNF-producing CD8+ T cells are
shown (data are mean 6 s.d. for 4 to 9 mice per group as indicated). (C) ActOVA DC and peptide-DCs were cultured in the presence of proteosome
inhibitors and the H-2K
b-restricted NP324–332 peptides (1 ug/ml). Acid washing elutes surface MHC-bound peptides and was used to confirm the
inhibition of antigen processing by the inhibitors. Shown are the cell surface levels of OVA257–264-MHC class I complexes. (D) DT-treated or untreated
CD11c-DTR BMCs were injected with 10,000 LCMV P14 T cells, followed by vaccination with B6 bone marrow derived DCs pulsed with 1 ug/ml of
LCMV gp33–41 peptides (peptide-DCs, 0.5610
6 cells/mouse). On Day 7 post-vaccination, the frequencies of IFN-c producing CD8+ T cells (data are
mean 6 s.d. of 5 mouse per group) were determined.
doi:10.1371/journal.pone.0011144.g004
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between days 8 and 9. To prepare mature DCs for vaccination,
they were cultured with lipopolysaccharide (LPS, 100 ng/ml,
Sigma Aldrich) for 15 hours. Peptide-pulsed DCs were prepared
by incubating LPS-matured DCs with 100 ng/ml of peptides for
1 hour at 4uC.
Peptides and flow cytometry reagents
The peptides H-2K
b-restricted OVA257–264 (SIINFEKL) and
H-2D
b-restricted lymphocytic choriomeningitis virus (LCMV)-
derived gp33–41 (KAVYNFATM, natural epitope), and their
irrelevant peptide controls, H-2K
b-restricted sendai virus-derived
NP324–332 (FAPGNYPAL) and H-2D
b-restricted influenza A-
derived NP366–374 (ASNENMETM) were purchased from Sigma
Aldrich. OVA257–264-specific tetramers were generated by the
Vaccine and Cell Therapy facility at New York University School
of Medicine. The antibodies specific for CD3 (clone 145-2C11),
CD8 (clone 53.6.7), CD11c (clone N418), CD11b (clone M1/70),
CD62L (clone MEL-14), CCR7 (clone 4B12), IL-2Rb (clone 5H4),
CXCR3 (clone CXCR3-173), CD45.1 (clone A20), CD45.2 (clone
104), IL-2 (clone JES6-5H4), IFN-c (clone XMG1.2), and TNF
(clone MP6-XT22) were purchased from Biolegend. Antibodies
specific for KLRG-1 (clone 2F1), Bcl-2 (clone 10C4), and
OVA257–264-MHC complex (clone eBio25-D1.16) were purchased
from eBioscience. Flow cytometry was performed using the FACS
Calibur (BD Biosciences). Analysis was done using FlowJo software
(Tree Star).
Peptide stability assay
Bone marrow derived DCs were incubated with the proteasome
inhibitors epoxomicin (0.5 mM, Sigma Aldrich) and clasto-Lacta-
cystin beta-lactone (1 mM, Sigma Aldrich) for the length of time
indicated. To confirm inhibition of antigen presentation, acid
washing on a portion of the DCs was done after 15 hours of
culture. Briefly, cells were washed with PBS, incubated with
0.131 M sodium citrate and 0.066 M sodium phosphate pH 3.3
for 2 min at room temperature. The cells were washed 3 times and
cultured in the presence of inhibitors again.
Generation of bone marrow chimeras (BMCs)
Host mice were supralethally irradiated with a split dose of
1300 rad delivered 3 hours apart using a cesium source (Gamma-
cell 40) at a dose rate of 95 rad/min. Following irradiation the
mice were reconstituted with 2610
6 bone marrow cells that were
depleted of T cells using anti-CD90 (Thy1.2) (Miltenyi Biotec)
magnetic bead separation. For 2 weeks following irradiation, the
BMCs were maintained on aqueous antibiotics by supplementing
their drinking water with 0.4% Trimethoprim Sulfa (Sigma),
which was changed every 3 days. The mice were used 8–12 weeks
after engrafting.
In vivo killing assay
The generation of an adaptive immune response by vaccination
was analyzed by testing the ability of the immune system to kill
target cells in vivo in an antigen-specific manner. To prepare the
target cells, splenocytes from naı ¨ve C57BL/6 mice were divided
into 2 groups, and incubated with 1 mg/ml of either OVA257–264
peptides or an irrelevant peptide for 1 hour at 37uC in serum-free
RPMI. Next, the cells were washed and each group was stained
with a different concentration (5 mM and 1.25 mM) of carboxy-
fluorescein succinimidyl ester (CFSE, Invitrogen) in PBS for 10
minutes. After extensive washing the cells were mixed at equal
proportions and injected intravenously at 5.0610
6 cells/mouse
into the previously vaccinated mice. After the number of days
indicated, in vivo killing of the target cells in the spleen of each
mouse was evaluated using flow cytometry.
OT-1 CD8+ T cell proliferation assay
Naı ¨ve CD8+ T cells from OT-1 Rag-/- mice were isolated and
stained with CFSE (5 mM). For the in vitro assay, these cells were
co-cultured with different concentrations of APCs in a U-bottom
96-well plate. On day 3, the cells were stained with antibodies for
the T cell markers, CD3 and CD8. 7-AAD was used to gate out
dead cells. Flow cytometry was used to analyze CFSE dilution that
occurs with each cell division.
Ex vivo T cell stimulation and intracellular staining
Splenocytes from previously vaccinated mice were stimulated
with peptide-pulsed CFSE-labeled naı ¨ve splenocytes from wild
type mice in the presence of monensin (Biolegend) for 5 hours at
37uC. Next, cells were surface stained with antibodies against CD3
and CD8, followed by intracellular staining with antibodies against
either IFN-c or TNF. The final percentage of antigen-specific
CD8+ T cell response was determined after gating out CFSE+
cells and subtracting the percentage of cytokine producing CD8+
T cells in the samples from each mouse that were stimulated with
an irrelevant peptide.
Statistical analysis
All statistical analysis was performed using a two-tailed unpaired
Student’s t test.
Supporting Information
Figure S1 Generation of donor-specific tolerance by allogeneic
bone marrow transplantation. CFSE (5mM)-labeled 5.0610
6
splenocytes from C57BL/6 (B6) mice were injected into MHC I-
deficient (K
bD
b KO) mice, and bone marrow chimeric mice





b KORB6 BMC) bone marrow cells. Seven days later,
tolerance of the injected cells was measured by their presence
detected on flow cytometry.
Found at: doi:10.1371/journal.pone.0011144.s001 (4.30 MB TIF)
Figure S2 Peptide-MHC complexes are transferred to splenic
cell populations efficiently in a contact-dependent manner in vitro.
(A) To confirm that MHC class I-deficient cells cannot present
antigens, splenocytes from wild type (B6) mice and from MHC
class I-deficient K
bD
b KO mice were pulsed with OVA257-264
peptides at 100 ng/ml. Next, CD11c+ DCs and Gr-1+ cells were
sorted and co-cultured with CFSE-labeled naı ¨ve OT-1 CD8+ T
cells. Proliferation of the T cells was analyzed 3 days later. (B)
CD45.2+ splenocytes from either wild type B6 or K
bD
b KO mice
were co-cultured with 10 ng/ml OVA257-264-pulsed DCs
generated from wild type mice (B6.SJL) with a differential
congenic marker, CD45.1. The splenocytes and peptide-pulsed
DCs were co-cultured either directly or separated by a transwell
membrane overnight. Next, different CD45.2+ splenic cell
populations (CD11c+ DCs, B220+ B cells, and Gr-1+ cells) were
sorted and co-cultured with naı ¨ve OT-1 CD8+ T cells for 3 days,
after which proliferation of the T cells were analyzed. This
experiment was repeated twice.
Found at: doi:10.1371/journal.pone.0011144.s002 (6.15 MB TIF)
Figure S3 Depletion of endogenous cDCs in CD11c-DTR bone
marrow chimeras by diphteria toxin treatment. To deplete
endogenous cDCs during vaccination, CD11c-DTR bone marrow
chimeras (BMCs) were treated with diphteria toxin (DT) on days
Indirect Priming by DC Vaccine
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DC ablation in the spleen was confirmed in DT treated mice on
days 0 and 2 by staining for CD11b+CD11c
high+ cells.
Found at: doi:10.1371/journal.pone.0011144.s003 (4.71 MB TIF)
Figure S4 Peptide transfer is not due to non-specific binding of
peptides on ex vivo generated DCs. DCs generated from either
C57BL/6 or K
bD
b KO mice were pulsed with OVA257-264
peptides (1 ug/ml) for 1 hour at 4uC. After extensive washing, the
cells were injected (0.5610
6 cells/mouse) into bone marrow
chimeras generated by reconstituting lethally irradiated K
bD
b
KO mice with bone marrow from B6 mice (B6R K
bD
b KO
BMCs). On day 6, antigen specific T cell responses were
determined by measuring the percentage of OVA257-264-
tetramer, IFN-c, or IL-2 positive CD8+ T cells.
Found at: doi:10.1371/journal.pone.0011144.s004 (4.63 MB TIF)
Figure S5 Stage specific phenotype of CD8+ T cells primed in
the presence or absence of endogenous CD11c+ DCs is similar.
Diptheria toxin (DT) treated or untreated CD11c-DTR bone
marrow chimeras (BMCs) were vaccinated with either OVA257-
264-pulsed DCs (peptide-DCs) or ActOVA DCs as in Fig. 4B.
OVA257-264-tetramer positive CD8+ T cells in the spleens on
day 7 were stained with specific markers (CD62L, KLRG-1,
CCR7, CXCR3, Bcl-2, and IL-2Rb) to determine their effector or
memory stage.
Found at: doi:10.1371/journal.pone.0011144.s005 (9.53 MB TIF)
Figure S6 Splenic DCs upregulate maturation markers in mice
injected with LPS-treated in vivo derived DCs. C57BL/6 mice were
injected with either immature DC or LPS-DCs, or left untreated.
Approximately 24 hours later, splenic CD11c
high DCs were
analyzed for expression levels of CD86 and CD40.
Found at: doi:10.1371/journal.pone.0011144.s006 (0.42 MB TIF)
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